Secondary GBMs with IDH1 mutations are mostly developed from grade II gliomas, whereas secondary GBMs lacking IDH1 mutations are progressed from grade III gliomas via additional genetic, epigenetic, or chromosomal alterations making them more aggressive [24,25]. This evidence concerns the gene IDH1 and central nervous system cancer.